ImmunityBio, Inc. has exhibited dramatic revenue growth fueled predominantly by its ANKTIVA bladder cancer treatment, with sales expanding over 700% year-over-year in 2025 following EU regulatory nods and broader commercial availability. Despite the top-line momentum, the company remains unprofitable with significant operating losses and negative cash flows reflecting ongoing development and commercialization expenses. ImmunityBio’s future trajectory hinges on execution in scaling ANKTIVA sales internationally, managing regulatory risks, and addressing a stretched balance sheet burdened by convertible debt. Investors should monitor upcoming regulatory milestones, market adoption rates of ANKTIVA combinations, and any shifts in capital strategy given the high burn rate.